Please assess the completion status of the following clinical trial:

Trial Title: A Trial of SHR-1703 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Caucasian subjects, male and female, 18 to 55 years of age, inclusive;~2. Body weight ≥45 kg (Both male and female), body mass index (BMI) between ≥19.0 and ≤29.9 kg/m2, inclusive;~3. No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry and coagulation function) and ECG at the investigator's discretion during screening and baseline.~4. Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods and have no plan to have a child from signing the consent form to 30-days after last scheduled follow-up visit.~Exclusion Criteria:~1. Known history or suspected of being allergic to the study drug.~2. Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency virus (HIV-Ab) at screening.~3. Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening or within 5 half-lives of any drugs during screening visit, or in the follow-up period of a clinical study whichever is longer~4. Use of any medicine within 4-weeks prior to the IP administration~5. Blood donation or loss of more than 400 mL of blood within 1 month of screening; or received blood transfusion within 2 months before screening.~6. Live (attenuated) vaccination within 1 month before screening or plan to be vaccinated~7. Severe injuries or major surgeries within 6 months before screening or plan to do surgeries during the trial~8. Patients with known or suspected parasitic infection within 6 months before screening~9. Either ALT, AST, ALP, GGT or total bilirubin level exceeds upper limit of normal range (ULN) at screening or baseline visits (confirmed by a single repeat, as per investigator's judgment)~10. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening.~11. History of alcohol abuse within 3 months prior to the IP administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SHR-1703 Dose Level 1 (Type: EXPERIMENTAL): Dose level 1 SHR-1703
- SHR-1703 Dose Level 2 (Type: EXPERIMENTAL): Dose level 2 SHR-1703
- SHR-1703 Dose Level 3 (Type: EXPERIMENTAL): Dose level 3 SHR-1703
- SHR-1703 Dose Level 4 (optional) (Type: EXPERIMENTAL): Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review

Based on this trial design, predict the completion outcome and termination type (if applicable).